The MuSPAD study (Nationwide Population-Based Study on Infectious Diseases) began on July 1 in Reutlingen as a pilot region and is being conducted as a successive cross-sectional study in several districts. Up to 40,000 participants are tested for specific antibodies against SARS-CoV-2, and the results are communicated to the participants after four weeks.
Within the project “MuSPAD integrated into the German National Cohort (NAKO) at the Hannover study site” (MuSPAD in NAKO, n = 3,000 participants), participants of the German National Cohort (NAKO) are invited to take part additionally in MuSPAD. The results derived from the combination of MuSPAD and NAKO data are intended to contribute to the improvement of public health strategies and to create a public good for the health of the population in Germany.
